Trv Gp V LLC Invests $261.71 Million in Rapport Therapeutics, Inc. $RAPP

Trv Gp V LLC acquired a new position in Rapport Therapeutics, Inc. (NASDAQ:RAPP - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 6,280,525 shares of the company's stock, valued at approximately $261,709,477. Rapport Therapeutics accounts for about 0.1% of Trv Gp V LLC's portfolio, making the stock its largest holding. Trv Gp V LLC owned about 13.09% of Rapport Therapeutics at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of RAPP. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Rapport Therapeutics by 86.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company's stock valued at $99,000 after purchasing an additional 4,582 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC bought a new stake in shares of Rapport Therapeutics during the 1st quarter worth about $2,039,000. Rhumbline Advisers lifted its position in Rapport Therapeutics by 40.1% in the first quarter. Rhumbline Advisers now owns 14,358 shares of the company's stock worth $144,000 after purchasing an additional 4,109 shares during the period. Geode Capital Management LLC increased its holdings in shares of Rapport Therapeutics by 5.5% in the second quarter. Geode Capital Management LLC now owns 333,159 shares of the company's stock valued at $3,789,000 after purchasing an additional 17,496 shares in the last quarter. Finally, Creative Planning bought a new stake in shares of Rapport Therapeutics in the second quarter worth about $121,000.

Insider Activity at Rapport Therapeutics

In related news, CEO Abraham Ceesay sold 28,958 shares of Rapport Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total value of $1,390,273.58. Following the completion of the sale, the chief executive officer directly owned 486,108 shares in the company, valued at $23,338,045.08. This trade represents a 5.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 73,034 shares of company stock valued at $3,484,157 in the last quarter. Corporate insiders own 12.48% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on RAPP shares. BTIG Research reaffirmed a "buy" rating and set a $65.00 target price on shares of Rapport Therapeutics in a report on Wednesday, August 19th. HC Wainwright increased their price target on Rapport Therapeutics from $40.00 to $66.00 and gave the company a "buy" rating in a research note on Wednesday, August 12th. Citigroup restated a "market outperform" rating on shares of Rapport Therapeutics in a research note on Tuesday, June 2nd. Truist Financial assumed coverage on shares of Rapport Therapeutics in a research note on Monday, May 18th. They set a "buy" rating and a $56.00 target price on the stock. Finally, William Blair initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 28th. They set an "outperform" rating for the company. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Rapport Therapeutics currently has an average rating of "Buy" and a consensus price target of $62.86.

Rapport Therapeutics Stock Performance

RAPP stock traded down $1.20 during midday trading on Friday, hitting $49.63. 116,513 shares of the company's stock were exchanged, compared to its average volume of 342,401. The company has a market cap of $2.38 billion, a PE ratio of -16.33 and a beta of 0.97. The stock's fifty day moving average price is $43.17 and its 200-day moving average price is $36.79. Rapport Therapeutics, Inc. has a one year low of $14.11 and a one year high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.07). On average, analysts expect that Rapport Therapeutics, Inc. will post -4.09 EPS for the current year.

Rapport Therapeutics Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.